These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 8187984

  • 1. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M.
    Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
    [Abstract] [Full Text] [Related]

  • 2. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M, Pospai D, Forestier S, Vatier J, Vallot T.
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [Abstract] [Full Text] [Related]

  • 4. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E.
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [Abstract] [Full Text] [Related]

  • 5. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [Abstract] [Full Text] [Related]

  • 6. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
    Hirschowitz BI, Simmons J, Mohnen J.
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
    [Abstract] [Full Text] [Related]

  • 7. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J, Laskowiec G.
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [Abstract] [Full Text] [Related]

  • 9. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
    Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, Gardner JD, Jensen RT.
    Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
    [Abstract] [Full Text] [Related]

  • 10. Lansoprazole: a comprehensive review.
    Zimmermann AE, Katona BG.
    Pharmacotherapy; 1997 Feb; 17(2):308-26. PubMed ID: 9085323
    [Abstract] [Full Text] [Related]

  • 11. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [Abstract] [Full Text] [Related]

  • 12. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
    Paul G, Ramdani A, Mignon M, Vallot T, Forestier S, Cadiot G, Ruszniewski P, Joubert-Collin M.
    Gastroenterol Clin Biol; 1994 Feb; 18(8-9):695-701. PubMed ID: 7875436
    [Abstract] [Full Text] [Related]

  • 13. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H.
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [Abstract] [Full Text] [Related]

  • 14. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A, Mignon M, Samoyeau R.
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [Abstract] [Full Text] [Related]

  • 15. Lansoprazole: a proton pump inhibitor.
    Garnett WR.
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [Abstract] [Full Text] [Related]

  • 16. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
    Hirschowitz BI, Simmons J, Mohnen J.
    Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
    Hirschowitz BI, Simmons J, Mohnen J.
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
    [Abstract] [Full Text] [Related]

  • 18. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI, Haber MM.
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [Abstract] [Full Text] [Related]

  • 19. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
    Wilcox CM, Seay T, Arcury JT, Mohnen J, Hirschowitz BI.
    Dig Liver Dis; 2011 Jun; 43(6):439-43. PubMed ID: 21193359
    [Abstract] [Full Text] [Related]

  • 20. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
    Wilcox CM, Seay T, Arcury J, Hirschowitz BI.
    Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.